GST Benefits New Revised MRP, 100% GST benefit passed
Intas Pharmaceuticals Ltd

TERIFRAC MULTI Pen(Device) 1's

Osteoporosis
Revised GST MRP ₹1,484.17 17.5% OFF 17.5% OFF (Inclusive of all taxes)
Deliver to

    Netmeds First Membership

    Starting at just ₹[] for 3 months.
    View Plans

    Introduction About TERIFRAC MULTI PEN(DEVICE)

    TERIFRAC MULTI PEN(DEVICE) is used in the management of osteoporosis. It contains a medicine called teriparatide which is an anabolic agent that is used to make the bones stronger, and to reduce the risk of fractures by stimulating bone formation.

    TERIFRAC MULTI PEN(DEVICE) works by causing the body to build new bone by increasing bone strength and bone mass density (BMD) (thickness) and reduce the risk of fractures by stimulating bone formation.

    TERIFRAC MULTI PEN(DEVICE) is not recommended for use in pregnant or breastfeeding women. It is also not recommended for use in patients with Paget’s disease, bone cancer or other cancers, certain bone diseases and hypercalcemia.

    The most common side effects of TERIFRAC MULTI PEN(DEVICE) are dizziness, leg cramps, mild headache, tachycardia, hypercalcemia symptoms such as nausea, vomiting, constipation, low energy, or muscle weakness. Consult your doctor if any of the above side effects worsens or persists for a longer duration.

    Uses Of TERIFRAC MULTI PEN(DEVICE)

    How TERIFRAC MULTI PEN(DEVICE) Works

    TERIFRAC MULTI PEN(DEVICE) works by causing the body to build new bone cells by increasing bone strength and bone mass density (BMD) (thickness) and reduce the risk of fractures by stimulating bone formation. It also increases the thickness of bone and rebuilds bones which reduces the risk of spine and hip fractures.

    How to use TERIFRAC MULTI PEN(DEVICE)

    • TERIFRAC MULTI PEN(DEVICE) can be administered by a doctor or nurse or can also be self-administered
    • Always inject this medicine into your thighs, buttocks, upper arm, or abdomen (i.e., subcutaneously). Do not administer this medicine into the vein or muscle directly.
    • Before administration, roll the vial/cartridge between your hands until the liquid becomes uniformly white and cloudy.
    • Follow your doctor's instructions carefully regarding the dosage and schedule.
    • Prior to the administration, visualize the cartridge/vial for any visible particulate matter and discoloration.
    • Discard the needle and syringe after use and do not share your needles with others to avoid the risk of transmission of infections.
    • Avoid repeatedly injecting the medicine at the same site to prevent skin damage. Instead, rotate the injection site. Make sure to consult your doctor before changing the injection site as a precaution.
    • Teriparatide should not be used for more than 2 years over a lifetime.
    • Your doctor will decide the correct dose and duration for you depending upon your age, body weight, and disease condition.

    Side Effects Of TERIFRAC MULTI PEN(DEVICE)

    Common Side Effects of TERIFRAC MULTI PEN(DEVICE):

    • dizziness
    • leg cramps
    • mild headache
    • tachycardia
    • hypercalcemia symptoms such as nausea, vomiting, constipation, low energy, or muscle weakness

    Warning & Precautions

    Pregnancy

    Contraindicated

    TERIFRAC MULTI PEN(DEVICE) is generally not recommended for use in pregnant women. Therefore, consult your doctor before receiving the medicine.

    Breastfeeding

    Contraindicated

    TERIFRAC MULTI PEN(DEVICE) is not recommended for use in breastfeeding women. Consult your doctor before receiving the medicine.

    Driving and Using Machines

    Contraindicated

    Do not drive or operate any machines if your ability is affected by TERIFRAC MULTI PEN(DEVICE).

    Alcohol

    Consult your doctor

    Avoid consumption of alcohol while receiving TERIFRAC MULTI PEN(DEVICE) because it might increase dizziness.

    Allergy

    Contraindicated

    Do not receive TERIFRAC MULTI PEN(DEVICE) if you are allergic to Teriparatide or any other ingredients of this medicine.

    Use In Pediatrics

    Contraindicated

    TERIFRAC MULTI PEN(DEVICE) is not recommended for use in children and adolescent (below 18 years), Proper dose adjustments and careful monitoring are required in such patients.

    Use In Geriatrics

    Use with Caution

    TERIFRAC MULTI PEN(DEVICE) should be used with caution in elderly patients (65 years and above). Consult your doctor before receiving the medicine.

    Others

    TERIFRAC MULTI PEN(DEVICE) is not recommended for use if you:

    • have Paget’s disease of the bone
    • have unexplained high levels of alkaline phosphatase in blood
    • have ever been diagnosed with bone cancer or other cancers that have spread (metastasized) in bones
    • have or had radiation therapy involving in bones
    • have certain bone diseases
    • have too much calcium in blood (hypercalcemia)

    Interactions

    A. Drug-Drug interactions:

    Tell your doctor about all the medicines you are taking including prescriptions, non-prescriptions and herbal or natural remedies.

    Overdosage:

    TERIFRAC MULTI PEN(DEVICE) will be administered to you only by a doctor or a nurse in a hospital, and so it is unlikely to receive an overdose. However, consult your doctor or nurse if you experience any unpleasant symptoms.

    Synopsis

    Drug :   Teriparatide
    Pharmacological Category :   Parathyroid hormone, Analogs
    Therapeutic Indication :   Osteoporosis          
    Dosage Forms :   Injection, PFS, Cartridge

    More Information

     

     

    FAQs About TERIFRAC MULTI PEN(DEVICE)

    Q: Can TERIFRAC MULTI PEN(DEVICE) be used in individuals with a history of cancer?

    A: TERIFRAC MULTI PEN(DEVICE) is generally not recommended for individuals with a history of cancer, especially skeletal malignancies or bone metastases. The medication has been associated with an increased risk of osteosarcoma, and its safety in individuals with a history of cancer has not been well established.

    Q: Can TERIFRAC MULTI PEN(DEVICE) be used in men with Osteoporosis?

    A: Yes. TERIFRAC MULTI PEN(DEVICE) can be used in men with osteoporosis. While Osteoporosis is more commonly associated with women, men can also develop the condition. It can effectively increase bone density and reduce fracture risk in men with osteoporosis.

    Q: Can TERIFRAC MULTI PEN(DEVICE) be used in individuals with a history of fractures?

    A: TERIFRAC MULTI PEN(DEVICE) is commonly prescribed for individuals with a history of fragility fractures. Fragility fractures occur due to minimal trauma or impact and are often associated with osteoporosis. It helps to increase bone density and reduce the risk of future fractures in individuals with osteoporosis, including those who have previously experienced fractures.

    Q: Can TERIFRAC MULTI PEN(DEVICE) be used as a first-line treatment for Osteoporosis?

    A: TERIFRAC MULTI PEN(DEVICE) is typically not used as a first-line treatment for osteoporosis. It is usually considered when other osteoporosis medications are ineffective, or individuals have a high fracture risk. However, whether it is appropriate as a first-line treatment depends on individual factors and should be discussed with your healthcare provider.

    Q: What are the potential long-term effects of TERIFRAC MULTI PEN(DEVICE)?

    A: The long-term effects of TERIFRAC MULTI PEN(DEVICE) have yet to be well understood, particularly beyond the recommended treatment duration of 2 years. The risk of osteosarcoma, a potential rare side effect, is one of the main concerns associated with long-term use.

    Q. Can I take this medication in long term for osteoporosis?

    A: TERIFRAC MULTI PEN(DEVICE) should not be taken for longer than 2-year course. It is important to inform the doctor if you have taken this medication in the past, as you should not receive more than one treatment of 24 months course more than once in your lifetime.

    Q: How does TERIFRAC MULTI PEN(DEVICE) works?

    A: TERIFRAC MULTI PEN(DEVICE) works by causing the body to build new bone by increasing bone strength and bone mass density (BMD) (thickness) and reduce the risk of fractures by stimulating bone formation. It also increases the thickness of bone and rebuilds bones which reduces the risk of spine and hip fractures.

    Q: Can TERIFRAC MULTI PEN(DEVICE) cause dizziness?

    A: Yes. TERIFRAC MULTI PEN(DEVICE) may cause dizziness in some individuals. Try to rest and relax. Get enough sleep. Avoid driving or operating machinery if you feel dizziness. Avoid alcohol consumption as it aggravates dizziness. Consult your doctor if the symptom does not improve.

    Q: Can TERIFRAC MULTI PEN(DEVICE) be given in children?

    A: TERIFRAC MULTI PEN(DEVICE) is not recommended for use in children and adolescents (below 18 years). Proper dose adjustments and careful monitoring are required in such patients.

    Q: How do you receive TERIFRAC MULTI PEN(DEVICE)?

    A: TERIFRAC MULTI PEN(DEVICE) will be given to you only by a doctor or a nurse subcutaneously into the thigh or abdominal wall. Your doctor will decide the correct dose and duration for you depending upon your age, body weight, and disease condition.

    References

    1. KD Tripathi, Hormones and Drugs Affecting Calcium Balance, Essentials of Medical Pharmacology, 8th Edition, 2019, 360-372.

    2. Hacen Vall; Preeti Patel; Mayur Parmar. Teriparatide.NIH:National Library of Medicine, National Center for Biotechnology Information. 29 Feb 2024. [Accessed on 03rd September 2024] click here

    3. PLIVA Hrvatska d.o.o. Emc. UK. [Revised in April 2023]. [Accessed on 21st October 2024] click here

    4. FORSTEO® 20 micrograms/80 microliters solution for injection in pre-filled pen teriparatide. Emc. UK. [Revised in January 2021]. [Accessed on 21st October 2024] click here

    5. Lilly France S.A.S. US Food and Drug Administration. [Accessed on 03rd September 2024] click here

    User Feedback

     

     

     

    Author Details

    Written By Srilekha. R - B.Pharm
    Reviewed For Accuracy By Dr. Jaya Prabakaran - MBBS, MD (Diabetology and Family Medicine)
    Last updated on 19 Nov 2024 | 10:37 AM(IST)
    Lab updated